Kurch, L; Hasenclever, D; Kluge, R; Georgi, T; Tchavdarova, L; Golombeck, M; Sabri, O; Eggert, A; Brenner, W; Sykora, K W; Bengel, F M; Rossig, C; Körholz, D; Schäfers, M; Feuchtinger, T; Bartenstein, P; Ammann, Roland; Krause, T; Urban, C; Aigner, R; ... (2019). Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatric blood & cancer, 66(3), e27539. Wiley-Liss 10.1002/pbc.27539
Text
Kurch_et_al-2019-Pediatric_Blood_&_Cancer.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (484kB) |
PURPOSE
In 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG-PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG-PET response corresponds to a visual Deauville score (vDS) of 5 and high qPET values ≥ 2. Evaluation in long-term outcome data is still pending. Therefore, we analyzed progression-free survival (PFS) by early FDG-PET response in a subset of the GPOH-HD2002 trial for pediatric Hodgkin lymphoma (PHL).
PATIENTS/METHODS
Pairwise FDG-PET scans for initial staging and early response assessment after two cycles of chemotherapy were available in 93 PHL patients. vDS and qPET measurement were performed and related to PFS.
RESULTS
Patients with a qPET value ≥ 2.0 or vDS of 5 had 5-year PFS rates of 44%, respectively 50%. Those with qPET values < 2.0 or vDS 1 to 4 had 5-year PFS rates of 90%, respectively 80%. The positive predictive value of FDG-PET response assessment increased from 18% (9%; 33%) using a qPET threshold of 0.95 (vDS ≤ 3) to 30% (13%; 54%) for a qPET threshold of 1.3 (vDS ≤ 4) and to 56% (23%; 85%) when the qPET threshold was ≥ 2.0 (vDS 5). The negative predictive values remained stable at ≥92% (CI: 82%; 98%).
CONCLUSION
Only strongly enhanced residual FDG uptake in early response PET (vDS 5 or qPET ≥ 2, respectively) seems to be markedly prognostic in PHL when treatment according to the GPOH-HD-2002 protocol is given.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Haematology/Oncology |
UniBE Contributor: |
Ammann, Roland |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1545-5009 |
Publisher: |
Wiley-Liss |
Language: |
English |
Submitter: |
Anette van Dorland |
Date Deposited: |
20 Feb 2019 09:45 |
Last Modified: |
05 Dec 2022 15:24 |
Publisher DOI: |
10.1002/pbc.27539 |
PubMed ID: |
30426671 |
Uncontrolled Keywords: |
F18-FDG-PET GPOH-HD2002 trial pediatric Hodgkin lymphoma (PHL) qPET quantitative Deauville score (qDS) visual Deauville score (vDS) |
BORIS DOI: |
10.7892/boris.123831 |
URI: |
https://boris.unibe.ch/id/eprint/123831 |